Literature DB >> 12195562

Human papillomavirus molecular biology and pathogenesis.

G Sanclemente1, D K Gill.   

Abstract

Human papillomavirus (HPV) infection is the most common sexually transmitted disease in the world and accounts for an estimated 11% of the global cancer incidence in women. HPV-16 is the most prevalent type detected in cervical cancer and along with types 18, 31, 33 and 45 has been classified as a class I carcinogen. In addition to cervical cancer, HPVs are also associated with the malignant transformation of other mucosal and skin cancers. Thus, the combination of the malignant potential of HPV and its high prevalence of infection confers to it an importance of generalized clinical and virological significance. The natural history of HPV infection with or without treatment varies from spontaneous regression to persistence. The most important mechanism for wart regression appears to be cell-mediated immunity. Cytokines released by keratinocytes or cells of the immune system may play a part in the induction of an effective immune response against HPV infection and the subsequent regression of lesions. This review discusses the molecular biology, pathogenesis and immunology of HPV infections.

Entities:  

Mesh:

Year:  2002        PMID: 12195562     DOI: 10.1046/j.1473-2165.2002.00419.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  29 in total

1.  Genital warts: a comprehensive review.

Authors:  Valerie R Yanofsky; Rita V Patel; Gary Goldenberg
Journal:  J Clin Aesthet Dermatol       Date:  2012-06

Review 2.  Vaccination against human papilloma virus (HPV): epidemiological evidence of HPV in non-genital cancers.

Authors:  Ioannis N Mammas; George Sourvinos; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2010-07-18       Impact factor: 3.201

3.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

4.  Carboxyl terminus truncated human papillomavirus type 58 L1 protein maintains its bioactivity and ability to form virus-like particles.

Authors:  Wensheng Li; Hongli Liu; Jin Zheng; Hongwei Chen; Jun Yang; Lixiu Wang; Xiaofei Yan; Yili Wang; Lüsheng Si
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

5.  Determining oxidant and antioxidant status in patients with genital warts.

Authors:  Erdem Cokluk; Mehmet Ramazan Sekeroglu; Mehmet Aslan; Ragip Balahoroglu; Serap Gunes Bilgili; Zubeyir Huyut
Journal:  Redox Rep       Date:  2015-01-13       Impact factor: 4.412

Review 6.  An armamentarium of wart treatments.

Authors:  Michelle M Lipke
Journal:  Clin Med Res       Date:  2006-12

7.  Risk factors for anogenital human papillomavirus infection in men.

Authors:  Carrie M Nielson; Robin B Harris; Eileen F Dunne; Martha Abrahamsen; Mary R Papenfuss; Roberto Flores; Lauri E Markowitz; Anna R Giuliano
Journal:  J Infect Dis       Date:  2007-09-17       Impact factor: 5.226

Review 8.  Human papilloma virus (HPV) infection in children and adolescents.

Authors:  Ioannis N Mammas; George Sourvinos; Demetrios A Spandidos
Journal:  Eur J Pediatr       Date:  2008-12-03       Impact factor: 3.183

9.  Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women.

Authors:  Nancy A Hessol; Elizabeth A Holly; Jimmy T Efird; Howard Minkoff; Karlene Schowalter; Teresa M Darragh; Robert D Burk; Howard D Strickler; Ruth M Greenblatt; Joel M Palefsky
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

10.  HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma.

Authors:  Jing Jie Yu; Pingfu Fu; John J Pink; Dawn Dawson; Jay Wasman; Jackson Orem; Walter O Mwanda; Honglan Zhu; Xiaobing Liang; Yi Guo; William P Petros; Ronald T Mitsuyasu; Henry Wabinga; Scot C Remick
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.